EQT
51
-11
GD
56
-7
CAH
57
-6
EMC
6
-9
COP
34
-20
HAS
43
-15
EXR
40
-10
EQIX
50
-5
BAX
38
-10
COF
50
-14
AIZ
66
-9
CA
13
3
EA
44
-5
AN
30
-8
GLW
37
-9
DAL
22
-9
EMN
33
-10
APA
23
-19
AMT
59
7
EXPD
27
-20
EQT
51
-11
GD
56
-7
CAH
57
-6
EMC
6
-9
COP
34
-20
HAS
43
-15
EXR
40
-10
EQIX
50
-5
BAX
38
-10
COF
50
-14
AIZ
66
-9
CA
13
3
EA
44
-5
AN
30
-8
GLW
37
-9
DAL
22
-9
EMN
33
-10
APA
23
-19
AMT
59
7
EXPD
27
-20
Financhill
Back

Catalyst Pharmaceuticals Stock Predictions

The Tariff-Proof Asset in Your Pocket

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
73

CPRX
Catalyst Pharmaceuticals

Last Price:
$24.10
Seasonality Move:
6.55%

7 Day Trial

ALL ACCESS PASS

$ 7

Meet the founder that's revolutionizing smartphones

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

Catalyst Pharmaceuticals Stock Forecast

  • Over the next 52 weeks, Catalyst Pharmaceuticals has on average historically risen by 39.3% based on the past 18 years of stock performance.
  • Catalyst Pharmaceuticals has risen higher in 10 of those 18 years over the subsequent 52-week period, corresponding to a historical accuracy of 55.56%
  • Is Catalyst Pharmaceuticals Stock Undervalued?
    The current Catalyst Pharmaceuticals [CPRX] share price is $24.11. The Score for CPRX is 73, which is 46% above its historic median score of 50, and infers lower risk than normal.
  • CPRX is currently trading in the 70-80% percentile range relative to its historical Stock Score levels.

Will Catalyst Pharmaceuticals Stock Go Up Next Year?

  • Over the next 52 weeks, Catalyst Pharmaceuticals has on average historically risen by 39.3% based on the past 18 years of stock performance.

Catalyst Pharmaceuticals Stock Rating

Buy
73
Catalyst Pharmaceuticals (CPRX) is a Buy

Is Catalyst Pharmaceuticals overpriced?

  • Catalyst Pharmaceuticals has risen higher in 10 of those 18 years over the subsequent 52-week period, corresponding to a historical accuracy of 55.56%

Catalyst Pharmaceuticals Stock Price History

Is CPRX stock going to rise?

  • Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and CPRX is experiencing buying pressure, which is a positive indicator for future bullish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
catalystpharma.com

52-Week Data

52-Week High:
26.16
52-Week Low:
14.47

Prediction Charts

Market Cap:
2.9B
Price in USD:
24.11
Volume:
1.3M
Beta:
1.09

Technical Analysis

SMA50:
22.83
SMA100:
22.33
SMA200:
20.52
52-Wk Change:
55.65%

Stock Predictions

  • Is Catalyst Pharmaceuticals stock public?
    Yes, Catalyst Pharmaceuticals is a publicly traded company.
  • What is the Catalyst Pharmaceuticals stock quote today?
    The Catalyst Pharmaceuticals stock price is 24.11 USD today.
  • How to buy Catalyst Pharmaceuticals stock online?
    You can buy Catalyst Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Mar-17 21.10 21.81 21.84 20.99
Mar-18 21.78 22.08 22.16 21.53
Mar-19 22.03 22.60 22.74 21.94
Mar-20 22.28 23.16 23.17 22.21
Mar-21 23.25 24.23 24.48 23.17
Mar-24 24.66 25.74 26.16 24.50
Mar-25 25.75 25.72 26.01 25.43
Mar-26 25.94 25.15 25.96 25.02
Mar-27 25.08 24.84 25.40 24.64
Mar-28 24.90 24.69 24.98 24.25
Mar-31 24.26 24.25 24.50 23.52
Apr-1 24.33 23.92 24.49 23.75
Apr-2 23.66 24.46 24.59 23.53
Apr-3 23.54 24.11 24.24 23.26

Catalyst Pharmaceuticals Earnings

Catalyst Pharmaceuticals Earnings Report: Per Share Catalyst Pharmaceuticals Earnings Q1 Q2 Q3 and Q4 last year and next year.

Catalyst Pharmaceuticals Forecast Revenue Growth

Catalyst Pharmaceuticals Stock Analysis: Historical quarterly revenues per share for Catalyst Pharmaceuticals and historical quarterly revenue growth:

  • Analysts estimate an earnings increase this quarter of $0.04 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.10 per share, and an increase next year of $0.37 per share.

* Catalyst Pharmaceuticals stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.